quantum dots

The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Quantum Materials and NanoAxis have forged a deal combining their technologies for diagnostic and pharmaceutical applications.

Quantum Materials and Nanoaxis this week announced a partnership that will see the firms pair their respective technologies to develop microarray-based tests for a variety of conditions.

Building on its experience in different technology areas, the company is currently developing the single-molecule platform, which it plans to start testing next year with external collaborators such as the J. Craig Venter Institute.

Short Reads

Premium

Life Technologies, J. Craig Venter Institute, BioNanomatrix, Nanosys, Geospiza, HDF Group, Pressure BioSciences, Cofactor Genomics, Ambry Genetics, Affymetrix, Navigenics, Enzymatics, New York State Department of Health, University of Washington

Life Technologies is looking to expand uses of its quantum dot technology beyond life sciences and into applied fields, such as counterfeit detection.

Proteins, Front and Center

Premium

Once a tool that only piqued the interest of technology developers, protein microarrays have come into their own as scientists find new ways to apply them in basic and translational studies.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.